Aeglea BioTherapeutics, Inc.has announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to ACN00177 for the treatment of Homocystinuria. Aeglea initiated a Phase 1/2 clinical trial earlier this year to investigate ACN00177 for the treatment of Homocystinuria. Read the Press Release here.